Institutional Equity Research for Undercovered Public Companies
Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.
Search AER-covered companies and Insights, or explore listed companies across global markets.
Latest Research
Recent initiation reports, research updates and company commentary from Alliance Equity Research.

Helus Pharma Inc.
HELP
HLP003 Achieves Statistically Significant Phase 3 Efficacy with Sustained Benefits Through Week 12, Supporting Higher Development Success Probability
HLP003 beat placebo by 7.6 points on the MADRS depression scale at Week 6 and by 7.0 points at Week 12. AER raises its illustrative valuation to $20.00 per share and examines three treatment-related serious adverse events, confirmatory trial timing, and quarterly cash use.

Helus Pharma Inc.
HELP
Phase 3 Depression Programme APPROACHes a Defining Clinical Readout as Its Proprietary Serotonergic Pipeline Targets Lasting Treatment Benefits in Depression and Anxiety
An in-depth analysis of Helus Pharma’s HLP003 and HLP004 programs, assessing clinical progress, competitive positioning, commercial potential, financing needs, and risk-adjusted valuation.


ASML Holding N.V.
ASML
A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality
Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.
Insights
Timely analysis of company developments, industry trends, capital markets activity, and emerging investment themes across global public markets.
Biotechnology & HealthcareSELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review
SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.
Biotechnology & HealthcareHelus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward
Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.
Biotechnology & HealthcareAmylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment
Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.
Biotechnology & HealthcareMilestone Extends Its Cash Runway as CARDAMYST’s Early Sales Lag Launch Costs
Milestone Pharmaceuticals plans to cut operating expenses by approximately 30% as it develops a second potential use for CARDAMYST, its newly launched heart-rhythm nasal spray. Third-quarter product sales reached $963,000, while a separate $2 million licensing milestone accounted for most reported revenue. Management expects its cash to support operations into late 2028, around the time of a Phase 3 readout. Investors must weigh improving prescription activity and insurance coverage against launch spending, sales-based financing obligations and the time needed to establish a sustainable commercial business.
Mining & Critical MineralsAtalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital
Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.
Biotechnology & HealthcareKura’s Leukemia Drug Sales Grow as Partnership and Financing Shape Future Returns
Kura Oncology’s first commercial medicine generated $13.9 million in third-quarter sales as more patients began treatment for a genetically defined form of acute myeloid leukemia. The launch is gaining traction, but Kura shares U.S. commercialization profits and losses with Kyowa Kirin and continues to fund extensive clinical development. A new Oberland Capital financing provides capital now and conditional access to more, alongside debt, equity issuance and a future sales-based obligation. The opportunity to treat newly diagnosed patients is larger than the current indication, but evidence from a Phase 3 program is not expected until 2028.
EnergyRWE and KKR Share Capital Commitments as £12 Billion Wind Projects Advance
RWE and KKR have completed their partnership and secured financing for two British offshore wind farms requiring approximately £12 billion of investment. Each partner will own half of the projects, while RWE leads construction and delivery. Long-term power contracts provide greater revenue visibility, and project-level financing will help support development through expected commissioning in 2030. For investors, the transaction shares RWE’s capital commitments but leaves important details undisclosed, including the partners’ individual contributions. Construction costs, timing and electricity generation will determine how much value the projects ultimately deliver.
Biotechnology & HealthcarePepGen’s DM1 Trial Shows Early Functional Improvements as Safety and FDA Questions Remain
PepGen reported that six patients receiving its experimental myotonic dystrophy treatment showed an average 46.5% correction on a muscle RNA measure, alongside improvements in hand opening and other functional tests. The Phase 2 findings support continued development, but the small cohort and short follow-up limit conclusions about clinical benefit. Earlier kidney-related findings and a U.S. partial clinical hold remain relevant as the company studies higher and longer dosing. A larger trial must show that molecular changes translate into durable improvements meaningful to patients.
Explore Coverage
AER-covered companies combine public-company information with our proprietary research, updates, and commentary.
Find AER-Covered Companies
Explore AER-covered companies by sector, region, and market capitalization.
Research Built Around the Model
Alliance Equity Research develops written company analysis and detailed financial models together. The model is used to test operating assumptions, financial outcomes, scenarios, and valuation frameworks.
- Fundamental company analysis
- Integrated financial modeling
- Scenario-based valuation framework
- Ongoing coverage after initiation
Operating Drivers
RevenuePricingVolumeKPIsFinancial Forecast
Illustrative forecast structure, without financial values Metric FY1 FY2 FY3 FY4 Revenue Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder EBITDA Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder FCF Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder Scenarios & Sensitivities
BaseUpsideDownsideValuation
DCF · Trading Multiples
Published Research
Is Your Company Undercovered?
Alliance Equity Research works with listed companies, recently listed companies, and businesses preparing to list, with a focus on undercovered, emerging, and high-potential opportunities. Our coverage includes initiation research, detailed financial modeling, and ongoing research updates.
- Initiation Research
- Financial Model
- Ongoing Updates
Investor Discovery
- AER Website
- FactSet
- LSEG Refinitiv
- AlphaSense
- Distribution Partners
Stay Current with AER
Choose the research and Insights updates you want to receive.
